NTRA stock forecast, quote, news & analysis
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology... Show more
Natera (NTRA) Stock Analysis: Precision Medicine Milestones in Focus
Key Takeaways
- Natera's stock has shown stability in recent trading sessions amid anticipation for first-quarter earnings on May 7, trading within its 52-week range.
- Recent clinical data presentations at major conferences underscore the growing clinical impact of Signatera for minimal residual disease (MRD) detection and Prospera for transplant monitoring.
- A court ruling awarding Natera a 30% ongoing royalty on MRD-related patents strengthens its intellectual property position.
- Analysts maintain a strong buy consensus with an average price target around $258, suggesting upside potential.
- Fiscal 2026 revenue guidance of $2.62 billion to $2.70 billion reflects robust growth expectations from oncology and transplant segments.
Current Market Snapshot
Natera's shares have maintained a steady presence in recent weeks, hovering in the middle of their 52-week range amid broader biotech sector fluctuations. The stock reflects measured investor confidence following strong prior-quarter performance, with year-to-date gains underscoring resilience in precision diagnostics. Trading volume has been consistent, signaling balanced interest as market participants position ahead of upcoming catalysts. Positive sentiment around cell-free DNA (cfDNA) technologies continues to support the stock, though macroeconomic pressures on healthcare spending introduce caution. Overall, NTRA exhibits poised momentum in the latest market cycle, balancing innovation-driven upside with sector headwinds.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of the platform's top-performing AI trading bots, drawn from a library of 351 bots that trade thousands of tickers across stocks, ETFs, and crypto. These bots employ diverse machine learning strategies, timeframes from 5 minutes to months, and themes like semiconductors, data centers, space industrials, small caps, volatility, gold miners, and finance. Only the most suitable for current market conditions earn a spot in this trending section, with standout performances including annualized returns up to 163%, win rates ranging from 50% to 88%, profit factors of 1.5 to 11.7, and favorable profit-to-drawdown ratios often exceeding 5:1. Whether swing trading or short-term corridor strategies (e.g., TP 3%/SL 2%), each bot offers unique risk profiles and sector focuses to suit various investor styles. Traders can explore these high performers for potential copy trading opportunities tailored to today's dynamic markets.
Recent Developments Driving NTRA Price Action
In the past 30 days, Natera has generated significant buzz through clinical advancements and legal wins, contributing to stable price action around the $200 level despite broader market volatility. On April 7, the company presented 20 abstracts at the American Association for Cancer Research (AACR) annual meeting, highlighting the scale, innovation, and clinical impact of its oncology platform. Data from over 75,000 patients demonstrated the utility of Signatera MRD testing across multiple cancers, reinforcing its role in personalized treatment decisions and boosting investor sentiment around adoption growth.
Two days later, on April 9, a judge awarded Natera a 30% ongoing royalty for its MRD-related patents, likely in ongoing litigation with competitors in the cfDNA space. This decision validates Natera's pioneering IP in tumor-informed MRD detection, potentially providing a recurring revenue stream and deterring infringement, which helped stabilize shares amid profit-taking.
April 13 brought further validation when Natera highlighted positive interim futility analysis from Allogene Therapeutics' MRD-guided ALPHA3 trial in large B-cell lymphoma. The trial utilized Signatera to guide treatment, showing promising signals that could expand MRD applications in immunotherapy, enhancing Natera's partnerships and market positioning.
On April 22, Prospera evidence featured in 17 presentations at the International Society for Heart and Lung Transplantation (ISHLT) meeting, showcasing its efficacy in heart and lung transplant monitoring. This builds on organ health momentum, diversifying beyond oncology.
Analyst coverage remained supportive, with William Blair initiating an Outperform rating around mid-April, citing Natera's leadership in precision oncology.
Capping the period, Natera announced on April 30 its Q1 2026 earnings release for May 7, following robust Q4 2025 results with 40% revenue growth to approximately $666 million. These developments have kept shares range-bound in recent sessions, as investors digest clinical tailwinds and await confirmation of sustained growth trajectories. The lack of major selloffs reflects confidence in Natera's execution, tempered by pre-earnings positioning.
2026 Outlook and Key Factors to Monitor
As Natera progresses through 2026, investors should track execution against its fiscal year revenue guidance of $2.62 billion to $2.70 billion, driven by oncology MRD expansion via Signatera and organ transplant monitoring with Prospera. Key themes include accelerating clinical adoption, with ongoing trials like Allogene's ALPHA3 and potential FDA approval of Signatera as a companion diagnostic (PMA submitted earlier this year). Reimbursement progress for cfDNA tests remains critical amid payer negotiations.
Opportunities lie in technology synergies, such as AI foundation models and partnerships like NVIDIA for bioinformatics acceleration, enhancing diagnostic accuracy and scalability. Risks encompass competitive pressures in the MRD market, regulatory hurdles, and macroeconomic impacts on healthcare budgets. Intellectual property enforcement, including royalty collections, could provide financial stability. Broader industry shifts toward precision medicine favor Natera's positioning, but margin expansion and test volume growth will be pivotal metrics. Balanced monitoring of these factors will inform strategic investment decisions throughout the year.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
NTRA in upward trend: 10-day moving average moved above 50-day moving average on April 14, 2026
The 10-day moving average for NTRA crossed bullishly above the 50-day moving average on April 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NTRA advanced for three days, in of 313 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 285 cases where NTRA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on May 14, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NTRA as a result. In of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for NTRA turned negative on May 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at .
NTRA moved below its 50-day moving average on May 13, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NTRA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
NTRA broke above its upper Bollinger Band on May 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock slightly better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.038) is normal, around the industry mean (12.548). P/E Ratio (0.000) is within average values for comparable stocks, (92.524). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.209). NTRA has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.018). P/S Ratio (10.309) is also within normal values, averaging (17.960).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. NTRA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a genetic testing company which develops proprietary bioinformatics-based technology
Industry MedicalSpecialties